Payment overview · 2025
General Payments
$89,539.50
175 reported records · 23 companies
Healthcare provider profile · identity verified
Brian C. Kolski, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · ORANGE, CA · NPI 1851449896
Verified facts
What the public records show
CMS Open Payments records show Brian C. Kolski, MD received $89,539.50 in general payments during 2025 across 175 reported records.
CORDIS US CORP. accounted for 45.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $40,587.18 | 45.3% | 31 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $22,390.03 | 25.0% | 22 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $8,547.21 | 9.6% | 21 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $7,684.14 | 8.6% | 18 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $5,520.03 | 6.2% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $2,262.24 | 2.5% | 31 | 2025 |
| AOP Health US, LLC | Unresolved — no canonical attribution shown | $692.81 | 0.8% | 1 | 2025 |
| Vesalio, Inc. | Unresolved — no canonical attribution shown | $500.00 | 0.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$458.07 | 0.5% | 11 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $193.37 | 0.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $115.22 | 0.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $99.80 | 0.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.04 | 0.1% | 4 | 2025 |
| InfoBionic, Inc | Unresolved — no canonical attribution shown | $81.24 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $63.57 | 0.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $43.97 | 0.1% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $42.98 | 0.1% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $37.64 | 0.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.94 | 0.0% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $29.85 | 0.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.32 | 0.0% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $18.30 | 0.0% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $16.55 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $38,200.00 | 11 |
| Travel and Lodging | $31,490.30 | 25 |
| Food and Beverage | $9,348.20 | 135 |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,375.00 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,126.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $22,390.03 | 22 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTA Normalized: selution slr pta |
Device | CORDIS US CORP. | $22,127.02 | 11 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $8,303.53 | 15 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $7,069.98 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $5,520.03 | 7 | 2025 |
Source payment records
|
|||||
| Rapiblyk Normalized: rapiblyk |
Drug | AOP Health US, LLC | $692.81 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $305.56 | 3 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTCA Normalized: selution slr ptca |
Device | CORDIS US CORP. | $280.57 | 8 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $253.71 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $241.57 | 7 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $193.37 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $183.86 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $141.33 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $115.22 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $99.80 | 5 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $94.04 | 4 | 2025 |
Source payment records
|
|||||
| MoMe Device Normalized: mome device |
Device | InfoBionic, Inc | $81.24 | 1 | 2025 |
Source payment records
|
|||||
| ATTAIN COMMAND + SUREVALVE Normalized: attain command surevalve |
Device | Medtronic, Inc. | $75.17 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $63.57 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $55.31 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $43.97 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $37.64 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $35.94 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $23.16 | 2 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| 2ND GEN CENTRIMAG PRIMARY CONSOLE Normalized: 2nd gen centrimag primary console |
Device | Abbott Laboratories | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
231 | 60 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
142 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
231 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 82 |
| Eliquis | Apixaban | 231 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 44 |
| Losartan Potassium | Losartan Potassium | 153 | 50 |
| Entresto | Sacubitril/Valsartan | 142 | 40 |
| Furosemide | Furosemide | 119 | 42 |
| Carvedilol | Carvedilol | 106 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 24 |
| Spironolactone | Spironolactone | 83 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 74 | 25 |
| Sotalol | Sotalol Hcl | 51 | 17 |
| Sotalol Af | Sotalol Hcl | 50 | 19 |
| Lisinopril | Lisinopril | 45 | 17 |
| Torsemide | Torsemide | 43 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 14 |
| Potassium Chloride | Potassium Chloride | 40 | 11 |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | 11 |
| Valsartan | Valsartan | 31 | 11 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Vyndamax | Tafamidis | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Repatha Pushtronex | Evolocumab | 15 | suppressed |
| Inpefa | Sotagliflozin | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89,539.50 · 175 records | CORDIS US CORP. | 2ND GEN CENTRIMAG PRIMARY CONSOLE, AMPLATZER AMULET, AMVUTTRA, ATTAIN COMMAND + SUREVALVE, Assure WCD, Barostim Neo System, CAMZYOS, CARDIVA VASCADE MVP VVCS 6-12F, COREVALVE EVOLUT R, DIAMONDBACK PERIPHERAL, EVOQUE, General - Balloon Catheters, KENGREAL, Kerendia, LEQVIO, LifeVest, MICRA, MYNX CONTROL VENOUS, MoMe Device, NAVITOR, Optimizer, PASCAL, PERCLOSE PROSTYLE, REPATHA, Rapiblyk, SAPIEN 3 Ultra RESILIA, SELUTION SLR PTA, SELUTION SLR PTCA, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VERQUVO, VYNDAQEL | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error